PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital)

N/A

Report date: 2022/02/17 14:20:01

Base Information

Drug NamePD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital)

Drug Alias Name抗PD-L1/CTLA4双特异性抗体PD-L1/CTLA4 BsAb

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors

TargetsProgrammed death-ligand 1Cytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesChanghai Hospital of Navy Medical University

China Registration ClassN/A

Develop Information

Active CompaniesChanghai Hospital of Navy Medical University

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A